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Abstract
Background: The placental syncytiotrophoblast releases micro and nanovesicles (STBM), into the maternal circulation in
normal pregnancy and in increased amounts in pre-eclampsia (PE), which have proinflammatory and antiangiogenic activity
and are implicated in PE pathophysiology. Better characterisation of STBM is essential to understand their role in PE.
Methods and Results: STBM prepared by placental lobe dual perfusion (pSTBM) and mechanical disruption (mSTBM) were
analysed by four colour flow cytometry (4CFC), nanoparticle tracking analysis (NTA) and Western blotting to determine
vesicle size, purity and Flt-1 and endoglin (Eng) expression. Biological activity of STBM associated Flt-1 and endoglin was
assessed by the ability of VEGF, PlGF and TGFb to bind to mSTBM and inhibit mSTBM induced endothelial monolayer
disruption. STBM content was consistently high (,87–95%) across the different preparations. However, surface antigen
intensities differed, with significantly lower placental alkaline phosphatase (P,0.05) and Eng (P,0.05) expression on
mSTBM, and Flt-1 (P,0.05) expression on pSTBM. For PE placenta derived preparations, pSTBM contained lower Eng
positive STBM (P,0.05) and mSTBM Eng expression was increased (P,0.05). Western blotting revealed increased Flt-1/sFlt-1
(P,0.02) and decreased placental alkaline phosphatase (P = 0.0002) content of PE placenta pSTBM. Using NTA, perfused PE
placentas released significantly larger MV (P,0.001). Finally, VEGF, PlGF and TGFb bound to mSTBM at physiologically
relevant concentrations and inhibited mSTBM induced endothelial disruption (P,0.05-P,0.001).
Conclusions: This study has found differences in physical and antigenic characteristics of normal and PE placenta STBM
preparations produced by placental perfusion or mechanical disruption. We have also demonstrated that large quantities of
biologically active STBM associated endoglin and Flt-1/sFlt-1 could contribute to the increased circulating levels measured
in PE patients and add to the perturbation of the maternal vascular endothelium, normally attributed to non-membrane
bound sFlt-1 and sEndoglin.
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Introduction
Pre-eclampsia (PE) is a complex disorder of human pregnancy,
which causes maternal and perinatal mortality or morbidity, and
has long-term health implications for mother and surviving off-
spring [1,2]. Its first (pre-clinical) stage comprises deficient
remodeling of the utero-placental circulation (8–18 weeks),
dysfunctional perfusion and placental oxidative stress [3,4]. The
second (clinical) stage (after 20 weeks) results from systemic
vascular inflammation. This has been shown to be an extension of
a broader maternal systemic inflammatory response intrinsic to
normal pregnancies, but more severe in pre-eclampsia, including
endothelial dysfunction, and metabolic, clotting and complement
disturbances. In searching for the cause of these changes in the
mother in PE, our attention has focused on the role of
syncytiotrophoblast derived vesicles (STBM). These are mem-
brane bound vesicles shed from the syncytial epithelium (STB) of
the placenta, that circulate during normal pregnancy and in
significantly increased amounts in PE [5,6].
Increasing evidence shows that STBM have functions relevant
to PE. We and others have shown that they bind to, and are taken
up by monocytes (both in vivo and in vitro), and stimulate the
production of proinflammatory cytokines [7–10], activate neutro-
phils [11],[12], inhibit endothelial cell proliferation and tube
formation or disrupt their growth as a monolayer [13–15], and
inhibit the relaxation of pre-constricted blood vessels [16]. We
have also shown that biologically active tissue factor on STBM
triggers thrombin generation and that PE STBM have significantly
higher TF levels than normal [17]. As well as having damaging
effects, STBM can also down-regulate maternal immune respons-
es. We and others have shown that STBM from normal placentas
inhibit T [18,19] and NK cell responses in vitro [20]. In order to
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understand the role of STBM in the maternal syndrome of PE, we
need to be able to characterise them more fully.
Since our initial observations of circulating STBM in normal
pregnancy and PE, the study of cellular vesicles in the biomedical
field has grown exponentially, with the discovery of multiple types
of cellular vesicles and their implication in a growing number of
diseases [21]. In general vesicles can be categorised as being either
microvesicles (MV: 100 nm –1 mm in diameter) which directly bud
from the plasma membrane and are released in response to cell
activation and death (apoptotic and necrotic) or nanovesicles
(exosomes 30 nm–100 nm) which are released by exocytosis from
multivesicular bodies of the endosome [21]. Microvesicles and
exosomes have different biological functions [22], cargoes and
modes of production. Microvesicles can be stimulatory or
inhibitory depending on whether they are generated early or late
during an inflammatory response [23]. Late response MV may
include apoptotic or necrotic material, the former immunosup-
pressive, the latter immunostimulatory [23]. Exosomes may also
be immunosuppressive, amongst other functions [22]. As discussed
above, there is evidence that STBM can be both immunostimu-
latory and immunosuppressive [9,10,18], possibly reflecting a
mixture of different vesicle types.
For experimental purposes, STBM can be produced ex vivo using
several methodologies, some of which are more representative of
in vivo STBM than others. Historically, ‘‘mechanically’’ derived
STBM (mSTBM), which as the name suggests, are produced from
mechanically disrupted villous tissue were used [24]. These are
highly disruptive to endothelial cell monolayers [13] and inhibit
endothelial cell and lymphocyte proliferation [25], but have
limited proinflammatory activity [10–12]. More recently, STBM
prepared from perfused placental lobules (pSTBM), which exhibit
both anti-endothelial and proinflammatory activity, have been
used [7,10,12], and are thought to be more representative of in vivo
derived STBM [12].
The aim of this study was to characterise STBM produced from
normal and PE affected placentas by these two methodologies,
mechanical disruption and placental lobe dual perfusion and
determine whether there were differences between those derived
from normal and PE placentas which might explain their different
functional properties. To do this we have developed a multicolour
flow cytometry technique which enables us to accurately define
STBM populations and the antigens they express. In particular we
have investigated the expression of two anti-angiogenic molecules,
fms-like tyrosine kinase 1 (Flt-1) and endoglin, both of which have
soluble forms significantly elevated in the maternal circulation in
PE and believed to play a role in the disorder. Western blotting for
these molecules has been carried out in parallel. Biological activity
of STBM associated Flt-1/soluble Flt-1 (sFlt-1) and endoglin was
demonstrated by assessment of the ability of mSTBM to bind the
ligands VEGF (vascular endothelial growth factor), PlGF (placen-
tal growth factor) and TGFb (transforming growth factor b),
required for maintenance of normal vascular endothelial function
[26], as well as the effects of these ligands on endothelial cell
disruption by mSTBM treatment in vitro. We also sought to
determine the size distribution of vesicles from mSTBM and
pSTBM preparations and whether there were differences between
those prepared from normal and PE placentas. It was not possible
to do this using flow cytometry as current digital instruments can
only detect vesicles down to approximately 300 nm in size and are
therefore not sufficiently sensitive to detect exosomes [27]. We
have therefore utilized a new technology, Nanoparticle Tracking
Analysis (NTA) which can measure cellular vesicles down to
approximately 50 nm in size which includes exosomes [27].
Finally, using Western blotting (WB), the presence of exosome
markers was investigated in normal and PE pregnancy placenta
derived mSTBM and pSTBM preparations.
Materials and Methods
Ethics Statement
The Central Oxford Research Ethics Committee C approved
this study and informed written consent was obtained from all
recruited individuals.
Tissue
Term human placentae (normal n = 22, PE n= 11) were
obtained from the delivery suite at the John Radcliffe Hospital,
Oxford from non-labouring healthy women with normal uncom-
plicated pregnancies and PE women, delivered by elective
caesarean section. Only placentae collected within 10 min of
delivery were used. Umbilical cords were obtained, with consent,
from uncomplicated normotensive term pregnancies delivered by
cesarean section (n= 5). Normal pregnant women were selected if
they had no history of hypertension or chronic illness, a singleton
pregnancy without known fetal abnormality, and natural concep-
tion. PE was defined as new hypertension (blood pressure $140/
90 mm Hg on two consecutive occasions) and new proteinuria
(24 h secretion of $500 mg), in the absence of urinary tract
infection.
Production of STBM
STBM produced by mechanical disruption
(mSTBM). Mechanically derived STBM (mSTBM) were pre-
pared by a previously published method [24] with modifications
outlined elsewhere [13]. In the present study, all buffers were
passed through a 0.1 mM filter to minimalize the interference of
background microparticles. Placentas were obtained from healthy
(n = 13) and PE (n= 4) women and were processed immediately.
Briefly, placenta tissue was scraped from villi and washed in ice
cold 100 mM CaCl2 then PBS before being stirred in 0.9% NaCl
buffer for 1 hour at 4uC. Cell debris was removed by
centrifugation in a Beckman J6-M centrifuge at 600 g for
10 min at 4uC, then the supernatant was centrifuged at
150,0006g for 45 min at 4uC in a Beckman L8-80M ultracen-
trifuge. The resultant pellets were pooled and washed in sterile
0.1 mM filtered phosphate buffered saline (fPBS) before finally
being resuspended in fPBS. Protein content was determined using
a BCA protein assay kit and aliquoted samples stored at 280uC
for subsequent analysis. Typical mSTBM yields were in the range
of 50–100 mg total protein.
STBM produced by placental perfusion
(pSTBM). Perfusion derived STBM (pSTBM) were prepared
using a dual placental perfusion system [28] modified as previously
described [10]. Placentas obtained at cesarean section without
labour, from healthy (n = 9) and pre-eclamptic (n = 7) women were
processed immediately and, following an equilibration period,
were perfused for 3 hr in a closed circuit. All perfusion media were
passed through 0.1 mM filters to minimalize background micro-
particles that would interfere in subsequent microvesicle analysis.
At the end of the 3 hr perfusion period, the maternal-side
perfusate was centrifuged in a Beckman J6-M centrifuge at 600 g
for 10 min at 4uC to remove large debris. The supernatant was
centrifuged at 150,0006g (maximum) for 1 hr at 4uC in a
Beckman L8-80 M ultracentrifuge to pellet the vesicles. The
resultant pellets were pooled and washed in fPBS before finally
being resuspended in fPBS to give a final protein content of 5 mg/
ml, as assessed using a BCA protein assay kit, and stored in
Characterisation of Placental Microvesicles
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e56754
aliquots at 280uC until subsequent use. Typical pSTBM yields
were in the range of 25–50 mg total protein.
Flow Cytometric Analysis of STBM
Flow cytometer set up and determination of limit of
detection. Analysis of mSTBM and pSTBM was carried out by
multicolour flow cytometry, using a BD LSRII Flow Cytometer
(BD Biosciences, Oxford UK) equipped with a 488 nm (blue) and
633 nm (red) laser. All data were analysed using FACS DIVA
software (Becton Dickinson, Oxford, UK). Firstly, the limits of
detection of the flow cytometer were established using standard
size calibration beads. This is a common approach that has been
used in many studies to set the size gate for microvesicle (MV)
analysis [29–32]. 1 mm Fluoresbrite YG microspheres (Poly-
sciences Europe GmbH, Eppelheim, Germany) and NIST
polystyrene YG microspheres; 200 nm, 290 nm, 390 nm,
590 nm (Thermo Scientific, Fremont, CA) were diluted accord-
ingly in fPBS and used to determine the optimum side scatter and
forward scatter voltages for MV detection with minimum
interference from background machine noise [27]. 1 mm Fluores-
brite YG microspheres were then used to set a 1 mm limit gate to
exclude larger debris and contaminating platelets from the
analysis. Events that fell into this gate were then classified as
being #1 mm in size. Logarithmic voltages were used for all
channels. As STBM sample events were collected over 2 mins, BD
Trucount tubes were run to monitor flow rate stability. Prior to
running STBM samples, fPBS was also analysed in triplicate for
2 mins to assess the level of background contaminating events.
Conjugated dyes and antibodies used for STBM
multicolour flow cytometry. The following membrane stain
and fluorescence conjugated antibodies were used for STBM
phenotyping. All of the antibodies and corresponding IgG controls
were mouse monoclonals and purchased directly conjugated to the
appropriate fluorochrome, with the exception of the in-house
NDOG2 monoclonal antibody and commercially purchased
unconjugated IgG1 isotype control antibody. Bio-maleimide
(Mal) conjugated to either Alexa 680 or Alexa 488 (Invitrogen)
was used as a general MV marker as it binds to sulphydryl groups
present in proteins. The NDOG2 antibody and its IgG1 control
were conjugated to either RPhycoerythrin (RPE) or fluorescein
isothiocyanate (FITC) using commercially available conjugation
kits (Lightning Link; Innova Biosciences) according to the
manufacturer’s instructions and was used to stain MV originating
from the syncytiotrophoblast (STB). NDOG2 is a STB specific
antibody that recognises placental alkaline phosphatase (PLAP)
[33]. Non-STB MV in the preparations were identified using W6/
32 conjugated to Alexa 647 (AbD Serotec) which binds to MHC
class I, expressed by all cells in the body except STB and
erythrocytes. Finally, the presence of the Flt-1/sFlt-1 and endoglin
(Eng) on STBM was demonstrated with the binding of anti-Flt-1
mouse MAb conjugated to allophycocyanin (APC) (R&D Systems)
and anti-endoglin mouse MAb conjugated to RPE (R&D
Systems). Prior to use, all antibodies and bio-maleimide were
filtered through Nanosep 0.2 mm centrifugal devices (Pall Life
Sciences) to minimalize interference by background microparti-
cles. All antibodies and bio-maleimide were also titrated to ensure
their use at the optimum concentration. Fluorochrome compen-
sation for multicolour STBM flow cytometry was set-up using BD
CompBeads (BD Biosciences) labelled with fluorescence conjugat-
ed antibodies and fluorescence bio-maleimide labelled STBM.
STBM sample preparation for multicolour flow
cytometry. Frozen aliquots of mSTBM and pSTBM were
thawed at 37uC. Prior to analysis, the vesicle content of each
sample was measured using the flow cytometer, to calculate the
sample volume required for a final event rate of ,40,000 events/
2 mins. This step was carried out to ensure a consistent
STBM:antibody ratio across samples. All samples were then
blocked with 0.2 mm filtered Fc receptor blocker (10 mL; Miltenyi)
for 10 min at 4uC before the addition of either fPBS (unlabeled
control), fluorescence conjugated IgG controls (conjugated IgG
negative control), or fluorescence conjugated Mal and fluorescence
conjugated antibody (labeled STBM). Due to the lack of a negative
control for Mal, a FMO (fluorescence minus one) tube was set up
for each sample, that contained fluorescence conjugated antibod-
ies alone (Mal FMO control) (Roederer 2002). Tubes were
incubated for 15 min at R/T in the dark. Stained samples were
then made up to 200 mL with fPBS and acquired immediately for
2 min on the flow cytometer (Becton Dickinson LSR II). Gates
were firstly set so that #1% of cells stained positive in the
appropriate negative controls. The cells labelled with the
antibodies of interest were then compared with the negative
control using Diva flow cytometry software (Becton Dickinson).
Flow cytometric determination of the purity of STBM
preparations. To assess the proportion of STBM and non-STB
derived MV contained in the four STBM preparation types
(normal and PE pSTBM and normal and PE mSTBM) a pooled
sample was generated for each, then appropriately diluted,
blocked with Fc receptor blocker and labelled with Mal-Alexa
488, NDOG2-RPE and W6/32-Alexa 647 in parallel with
appropriate controls. The flow cytometer was set up as outlined
above and all sample events collected over 2 min.
Four colour flow cytometric analysis. Four colour flow
cytometry was used to identify STBM and their associated
antigens. Individual pSTBM and mSTBM preparations from
normal and PE placentas were stained with the following reagents:
Mal-Alexa 680; NDOG2-FITC, anti Flt-1-APC and anti Eng-
RPE. Unlabeled, FMO control (containing NDOG2-FITC, anti
Flt-1-APC and anti endoglin-PE) and IgG negative control tubes
were also set up for each sample. All samples were run as
previously described.
STBM SDS PAGE and Western Blotting
For analysis of PLAP, Flt-1, endoglin, the exosome markers
Lamp I, Alix, CD63, CD9, TSG101 and actin, pSTBM and
mSTBM were lysed (on ice, 30 min) in SDS-PAGE sample buffer
containing protease inhibitor cocktail (Roche Diagnostics). Lysed
samples were then diluted in reducing (PLAP, Flt-1, endoglin,
Lamp I, Alix, CD9, TSG101 and actin) or non-reducing (CD63)
sample buffer to give a final protein concentration of 10 mg/30 mL
(PLAP, Flt-1, endoglin and actin) or 20 mg/30 mL (Lamp I, Alix,
CD63, CD9, TSG101 and actin). Samples were then boiled and
centrifuged (13,0006g for 10 min) prior to separation by SDS/
PAGE (Invitrogen) and semi-dry transfer to PVDF membrane
(Biorad). Non-specific binding was blocked with TBS-T (20 mM
Tris/HCl, 137 mM NaCl, 0.1% Tween-20, pH 7.6) containing
5% BLOTTO (Santa Cruz Biotechnology Inc.). Membranes were
incubated O/N with antibodies against PLAP (NDOG2), Flt-1
(Abcam), endoglin (G4484 mouse MAb gift from Prof Letarte,
University of Toronto), Lamp I (BD Transduction Laboratories),
Alix (New England Biolabs), CD63 (Abcam), CD9 (Abcam),
TSG101 (Abcam) or actin (Abcam) at 4uC, and then washed in
TBS-T, before incubation with the appropriate horseradish-
peroxidase-conjugated secondary antibody (Dako). All antibodies
were diluted in blocking buffer. After washing, blots were treated
with an enhanced chemiluminescence system (Pierce) and exposed
to Hyperfilm ECL (GE Health Care). The resultant band densities
were quantified using Image J software [Abramoff MD, Magelhaes
PJ, Ram SJ. Image Processing with Image. J Biophotonics Int
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2004;11:36e42], available from http://rsb.info.nih.gov/ij/and
actin densities used to normalize data.
mSTBM Binding of VEGF, PlGF and TGFb
To investigate the binding of VEGF121, VEGF165, PlGF and
TGFb to normal mSTBM a pool of 13 preparations were double
diluted in dilution buffer (PBS containing 4 mM EDTA, 0.1%
BSA and 0.001% tween 20 at pH 7.4). 1 ng/ml of either
VEGF121, VEGF165, PlGF, TGFb (R&D Systems) or vehicle
control was then added, the tubes vortexed and incubated at 4uC
overnight with gentle mixing. Tubes containing the equivalent
volume of dilution buffer plus 1 ng/ml VEGF121, VEGF165, PlGF
or TGFb but without mSTBM were set up in parallel to control
for any non-STBM related losses. All binding experiment tubes
were set up in triplicate. At the end of the incubation period the
tubes were ultracentrifuged to remove mSTBM (150,0006g for
1 hr at 4uC in a Beckman L8-80M ultracentrifuge) and the
supernatant assayed by ELISA (R&D Systems) to determine the
recovery of VEGF121, VEGF165, PlGF and TGFb relative to the
no STBM control.
Effect of VEGF, PlGF and TGFb on STBM Disruption of
Endothelial Cells in Culture
The effect of VEGF121, VEGF165, PlGF or TGFb treatment on
the disruption of endothelial cell monolayers by mSTBM
treatment was tested. Human umbilical vein endothelial cells
(HUVEC) were isolated and maintained as described previously
[34]. Cells between passages 4 and 5 were used for all experiments.
On day 1, HUVEC (90,000 cells/well) were plated out into 1%
gelatin coated 24-well plates in 500 mL HUVEC culture medium
(CM) (M199 containing l-glutamine supplemented with 10% (vol/
vol) heat-inactivated FCS, endothelial cell growth supplement
(ECGS; 30 mg/ml), heparin (90 mg/ml), and penicillin, strepto-
mycin, and neomycin (50 U/ml, 50 mg, and 100 mg/ml, respec-
tively). The cells were left for 48 h at 37uC in 5% CO2 and 95%
air to allow cells to grow to approximately 80–90% confluence.
On day 3, CM was removed and cells washed in basic CM (M199
containing l-glutamine supplemented with 10% (vol/vol) heat-
inactivated FCS and penicillin, streptomycin, and neomycin
(50 U/ml, 50 mg, and 100 mg/ml, respectively)) before treatments,
made up in basic CM, were added for 16 h. mSTBM (pool of 13
preparations from normal placentas) were tested at 75 mg/mL and
VEGF121, VEGF165, PlGF and TGFb tested at 100 ng/mL. At
the end of the treatment period the cells were washed with Hanks
balanced salt solution and stained with CMFDA (1 mM) for 1 h in
serum free CM (M199 containing l-glutamine and penicillin,
streptomycin, and neomycin (50 U/ml, 50 mg, and 100 mg/ml,
respectively)), before being washed with HUVEC CM and images
taken using a Leica DMIRE2 inverted fluorescence microscope,
Hamamatsu Orca camera and Simple PCI software. The resultant
images were analysed using Image J software, to obtain the
percentage HUVEC coverage by measuring the number of pixels
above a constant background threshold.
Nanoparticle Tracking Analysis of STBM Preparations
Size distribution profiles of mSTBM and pSTBM from normal
and pre-eclampsia placentas were obtained using Nanoparticle
Tracking Analysis (NTA) as described by Dragovic et al. (2011),
with minor modifications. In this system vesicles are visualised by
light scattering using a light microscope. A video is taken using a
high sensitivity camera and the NTA software tracks the Brownian
motion of individual vesicles and calculates their size and
concentration. All samples were analysed using an NS500
instrument (Nanosight Ltd, Amesbury, UK). Each sample was
diluted in PBS to give approximately 56108 vesicles/mL. The
samples were automatically introduced into the sample chamber
and ten video recordings of 20 seconds in duration were captured
at 30 second intervals on different aliquots of the sample. Shutter
speed and gain were optimised for biological vesicles in the 80–
250 nm size range. NTA post acquisition settings were also
optimised and kept constant between samples and each video was
then analysed to give the mean, mode and median vesicle size.
Nanoparticle Tracking Analysis of SH-SY5Y Exosomes
Neuroblastoma cell line SH-SY5Y exosomes were isolated and
their size distribution profile obtained using NTA as previously
described [35].
Statistical Analysis
Mann Whitney non parametric test was used for all compar-
isons. Statistical analyses were carried out using Prism software.
Values of p,0.05 were considered to be statistically significant.
Results
Patient Data
Demographic and clinical characteristics of the study partici-
pants are shown in Table 1. There was no significant difference in
parity (not shown) or maternal age at the time of booking. Body
mass index and maximum diastolic and systolic blood pressures
were all significantly higher in the PE patients compared to the
normal pregnant study participants (Table 1). As would be
expected, gestational age and birth weight were both significantly
lower in PE affected pregnancies (Table 1).
Four Colour Flow Cytometric Analysis
Flow cytometer detection limit and set up. We have
previously shown using a range of fluorescent beads (200 nm,
290 nm, 390 nm, 590 nm and 1 mm) analysed on forward scatter
(FSC) and side scatter (SSC) that the limit of sensitivity of our BD
LSRII flow cytometer is approximately 300 nm [27]. A gate was
therefore set to include beads of only 290 nm –1 mm (Figure 1A) to
minimise background noise. As the BD Trucount tubes used to
determine the number of vesicles present contain many contam-
inating particles of a size which fall within the microvesicle gate
(Figure 1B) the beads were run separately rather than with the
samples. The flow cytometer flow rate was shown to be stable
(typical inter-assay CV of 3% and intra-assay CV of 4% over a one
month period), while background contaminating events were kept
to a minimum (typical levels of 2.5% were obtained) with regular
cleaning of the flow cytometer (Figure 1C). FSC vs SSC profiles
clearly differed between pSTBM (Figure 1Di) and mSTBM
(Figure 1Dii), with mSTBM preparations from both normal and
PE placentas containing significantly fewer events ,1 mm in
diameter (P,0.01)(Figure 1Diii).
Microvesicle gating strategy. Phenotyping of MV was
carried out as follows: Crude events $300 nm#1 mm were
identified on a forward scatter (FSC) vs. side scatter (SSC) plot
(Fig. 2Ai). Aggregates were removed from the analysis by
displaying crude events $300 nm#1 mm on a FSC-Height Vs
FSC-Width plot and gating around the main population (Fig. 2Aii),
the results of which were then displayed on a SSC-Height Vs SSC-
Width plot (Fig. 2Aiii) and a gate again placed around the main
population. All fluorescence staining was then analysed on this
population of events $300 nm#1 mm [32].
Flow cytometric determination of the purity of STBM
preparations. The purity of the STBM preparations was
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determined using three colour flow cytometry. The total MV
population was identified as being the events $300 nm#1 mm
positive for Mal-Alexa 488 (Figure 2Aiv). The total MV
population was then displayed on PLAP vs W6/32 quadrant
plots to identify STBM (PLAP +ve W6/32–ve) and non-STBM
(PLAP –ve W6/32+ve) respectively (Figure 2B). No difference was
seen between normal and PE STBM and non-STBM content of
mSTBM (93.1% vs 93.8% and 0.1% vs 0% respectively)
(Figure 2Bi and ii). Pooled pSTBM preparations however showed
a difference in purity when prepared from normal or PE placentas.
The PLAP +ve vesicle content was higher in pSTBM preparations
from normal (94.6%) compared to PE (87.4%) placentas
Table 1. Patient details for normal pregnant (n = 22) and preeclamptic women (n = 11).
Perfusion Perfusion Mechanical Mechanical
Normal Pregnant (n=9) PE (n=7) Normal Pregnant (n =13) PE (n =4)
Age (yrs) 33 (26–38) 39 (24–44) 35 (25–43) 35 (28–39)
Gestation (Wks) 39 (38+1–42) 35+3 (30–39+1)* 39 (38+3–40+4) 37.5 (32+6–39)*
BMI 24.4 (17.6–42.5) 26.4 (22.3–39.1)** 26.1 (19.4–36.1) 27.8 (25–39)**
Maximum Systolic BP
(mmHg)
120 (105–137) 170 (150–205)*** 120 (100–150) 159 (150–170)***
Maximum Diastolic BP
(mmHg)
74 (40–83) 105 (96–155)*** 70 (30–80) 107.5 (90–118)***
Proteinuria (mg/24 h) NAD 1167 (660–5831) NAD 1027.9 (612–3481)
Birthweight (g) 3430 (2925–4156) 2268 (1200–3500)** 3787 (3155–4300) 2788 (1460–3417)**
Values expressed as median (range). *P,0.003; **P,0.001; ***P,0.0003. P values are results of Mann Whitney test comparison of normal vs PE within each
syncytiotrophoblast microvesicle preparation group. (NAD; nothing abnormal detected).
doi:10.1371/journal.pone.0056754.t001
Figure 1. LSRII Flow Cytometer set up. A) SSC & FSC voltages were adjusted to visualise 290 nm and 1 mm microspheres to establish the
microvesicle analysis gate. B) Trucount beads were analysed for two minutes demonstrating large numbers of background particles present in the
Trucount tube. C) Two minute analysis of 0.1 mm filtered PBS showing the low number of background events present. D) FSC vs. SSC density plots
with #1 mm gate of representative i) mSTBM and ii) pSTBM preparations and iii) barchart showing a significantly lower percentage of events #1 mm
in both normal and PE mSTBM compared to pSTBM. *P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0056754.g001
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(Figure 2Biii and iv). This was reflected predominantly by an
increase in the percentage of W6/32 and NDOG2 negative MV,
with 4.6% in normal compared to 11.1% in PE pSTBM
preparations (Figure 2Biii and iv).
Four colour flow cytometric analysis of STBM
phenotype. To determine whether mSTBM and pSTBM
expressed Flt-1 or endoglin, events $300 nm#1 mm were
displayed on a Mal vs PLAP quadrant plot to determine the
Mal and PLAP double positive MV (STBM) population
(Figure 2Ci). To determine the STBM positive for Flt-1 or
endoglin, the total MV population was then displayed on quadrant
plots of Flt-1 vs PLAP (Figure 2Cii) and Eng vs PLAP
(Figure 2Ciii). Finally, to determine the percentage STBM positive
for both Flt-1 and endoglin, a quadrant plot of Eng vs Flt-1 was
drawn showing the STBM population (Figure 2Civ).
Effect of Preparation Methodology and Preeclampsia on
Surface Antigen Expression of STBM
Analysis by flow cytometry revealed that placental MV
preparations, produced by either perfusion or mechanical
disruption and from normal or PE placentas, all contained
similarly high proportions of MV positive for PLAP, confirming
their STB origin (Figure 3Ai and Bi). Likewise, preparation
method and PE did not significantly affect the percentage of
mSTBM or pSTBM positive for Flt-1 (Figure 3Ai and Bi). Unlike
preparation method, PE significantly decreased the percentage of
pSTBM but not mSTBM positive for endoglin
(P,0.05)(Figure 3Bi). However, there were no significant differ-
ences between preparation methods or PE in the percentage of
STBM expressing both Flt-1 and endoglin (mSTBM norm
31.964.3% and PE 42.962.0; pSTBM norm 40.062.4% and
PE 28.866.0%). All Flt-1 positive STBM were double positive for
endoglin (Figure 2Civ).
The mean fluorescence intensity (MFI) for each antibody was
also investigated. The MFI indicates the amount of antigen carried
on each MV positive for that antigen. PLAP MFI was significantly
lower on normal mSTBM compared to pSTBM (P,0.05)
(Figure 3Aii and Bii). Expression analysis of Flt-1 and endoglin
on STBM showed several differences between the two method-
ologies used, with Flt-1 expression significantly lower and endoglin
significantly higher on normal pSTBM compared to mSTBM
(P,0.05) (Figure 3Aii and Bii). PE tended to decrease PLAP
expression on pSTBM, although this did not reach significance,
and significantly increased endoglin expression on mSTBM only
(P,0.05) (Figure 3Aii).
SDS PAGE and Western Blotting of STBM Preparations
Semi-quantitative WB analysis of mSTBM and pSTBM was
carried out to validate expression patterns seen with PLAP, Flt-1
and endoglin by flow cytometry and further investigate the form(s)
of Eng and Flt-1/sFlt-1 protein present in normal and PE
mSTBM and pSTBM. It is important to note that flow cytometry
was carried out on non-permeabilised vesicles which only
measures surface protein expression, whereas WB measures total
(both surface and intravesicular) proteins. For normal and PE
mSTBM, results of WB analysis showed no significant difference
in expression of PLAP, Flt-1 or endoglin (Fig. 4Ai and ii).
However, for pSTBM, PLAP levels were significantly lower on PE
derived STBM compared to STBM isolated from normal
pregnancy placentas (Fig. 4Bi and ii; P = 0.0002), a trend seen
with flow cytometry. Western blotting analysis of Flt-1/sFlt-1
clearly showed multiple forms corresponding to 90–100 kDa,
,115 kDa and 160–190 kDa present to varying degrees in all
samples. In mSTBM (Fig. 4Aii) and in pSTBM (Fig. 4Ai), Flt-1/
sFlt-1 isoforms tended to be more highly expressed in PE derived
STBM compared to STBM isolated from normal pregnancy
placentas. However, densitometric analysis showed significantly
higher total Flt-1 isoform expression in PE pSTBM only (P,0.02;
Fig4Bii) compared to those isolated from normal placentas.
Syncytiotrophoblast Microvesicle Binding of VEGF, PlGF
and TGFb
Having shown that Flt-1 and endoglin were present on STBM
we then sought to determine whether they might have a functional
role and bind ligands for Flt-1 (VEGF121, VEGF165, PlGF) and
endoglin (TGFb). These assays were only performed on a pool of
normal mSTBM (n=13) due to the availability of the material.
The results showed that mSTBM bound all four growth factors
(Figure 5 Ai and Aii). The use of VEGF121 (which lacks the
heparin binding domain (HBD)) and VEGF165 (which contains
HBD) in parallel enabled us to discriminate between VEGF
binding to surface receptors or heparan sulphate. PlGF-1, like
VEGF121, binds Flt-1 but does not contain a HBD. mSTBM
bound PlGF and VEGF 121 to a similar extent, but bound more
VEGF165, suggesting that both receptors and heparan sulphate
were responsible for binding (Fig. 5A). The capacity of mSTBM to
bind TGFb was much higher, as ,100–1000 fold less mSTBM
was required to bind 25% of the added TGFb compared to VEGF
and PlGF (Fig. 5B). As TGFb also contains a HBD, binding to
both endoglin and heparan sulphate was possible.
Effects of VEGF, PlGF and TGFb Treatment on Endothelial
Cell Disruption by mSTBM
As mSTBM were able to bind VEGF121, VEGF165, PlGF and
TGFb, we wanted to investigate whether these Flt-1 and endoglin
ligands could reduce HUVEC monolayer disruption by mSTBM
in vitro. As shown previously [13] mSTBM significantly disrupted
the HUVEC monolayer (P,0.001; Figure 5B and C). All of the
ligands tested significantly blocked the disruptive effects of
mSTBM, shown by increased HUVEC coverage in the presence
of mSTBM and ligand compared to mSTBM treatment alone
(VEGF121, VEGF165 and TGFb P,0.001, PlGF P,0.05;
Figure 2. Four colour flow cytometric analysis of placental microvesicles. Representative results for pSTBM analysis are shown in A(i-iv) and
C(i-iv). Phenotyping of MV was carried out as follows: (Ai) Crude events .290 nm,1 mM were identified by FSC vs. SSC. (Aii) Aggregates were
removed from the analysis using FSC-Height Vs FSC-Width, (Aiii) followed by SSC-Height Vs SSC-Width plots to resolve events .290 nm,1 mM. (Aiv)
The total MV population was identified as bio-maleimide positive within this gate and this population was then used in subsequent analyses of MV
associated ligands. pSTBM and mSTBM preparation purity was assessed using quadrant plots of NDOG2 (anti-placental alkaline phosphatase (PLAP)
antibody) vs W6/32 (anti-MHC class I antibody) displaying the total MV population to identify syncytiotrophoblast derived MV (STBM) and other
contaminating MV in (Bi, iii) normal pregnancy and (Bii, iv) preeclampsia (Bi, ii) mechanical and (Biii, iv) perfusion derived MV preparations
respectively. The expression of Flt-1 and endoglin were investigated as follows: (Ci) Total MV and STBM populations were identified using bio-
maleimide-Alexa 680 (Mal) staining and Mal with NDOG2-FITC double staining, respectively. Flt-1 or endoglin positive placental MV were identified by
displaying the total MV population on either a (Cii) Flt-1-APC Vs NDOG2-FITC or (Ciii) endoglin-PE Vs NDOG2-FITC quadrant plot. Finally, (Civ)
endoglin/Flt-1 double positive placental MV were identified by plotting Mal/NDOG2 double positive MV onto an endoglin-PE Vs Flt-1-APC quadrant
plot. (D) Flow chart to describe the flow cytometric identification of syncytiotrophoblast derived microvesicles.
doi:10.1371/journal.pone.0056754.g002
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Figure 5C). When treated with ligand alone, only VEGF121 and
VEGF165 stimulated HUVEC proliferation, evident by increased
HUVEC coverage compared to untreated controls (Figure 5Ci
and 5Cii).
Nanoparticle Tracking Analysis (NTA) of STBM and
Exosome Marker Expression
STBM were analysed using NTA to determine their size
distribution, which relates to their composition in terms of
exosomes and microvesicles. We first analysed a preparation of
vesicles derived from the culture supernatant of neuroblastoma cell
line SH-SY5Y. These were found to have a peak modal size of
93 nm, with a size range of 50–250 nm, consistent with that of
exosomes (Fig. 6A). We next analysed 13 mSTBM preparations
from normal placentas and 4 mSTBM from PE placentas where
the modal peak size and size range were 140–235 nm and 50–
500 nm respectively (Fig. 6B), suggesting that mSTBM prepara-
tions contain both exosomes and microvesicles. There was no
difference in the size distribution profiles between the mSTBM
from normal and PE placentas. pSTBM had a similar size
distribution, with vesicles ranging from 50–500 nm and modal
peak size between 111–211 nm (Fig. 6C). However, PE derived
pSTBM (n= 7) showed a significant increase in both median
(P = 0.004) and modal size (P,0.001; Fig. 6C) compared to
normal placenta pSTBM (n= 9) (201 nm vs 166 nm and 191 nm
vs 149 nm respectively). This suggests that pSTBM from PE
placentas contain fewer vesicles in the exosome size range and
more in the microvesicle range, which may reflect different
patterns of shedding in the disease state. It is also clear from NTA
that both pSTBM and mSTBM contain a large number of vesicles
(.75%) undetectable by flowcytometry (ie. smaller than
,300 nm) (Fig. 6).
Western blotting of mSTBM and pSTBM was carried out for
Lamp1, Alix, CD63, CD9 and TSG101 to confirm the presence of
exosomes. All of the exosome markers except TSG101 were
detectable at varying levels (Fig. 6D), although were no significant
differences between the types of vesicles (mSTBM v pSTBM).
Only CD63 showed a significant elevation on both mSTBM and
pSTBM from pre-eclampsia placentas compared to normal
(P,0.05 and P,0.03 respectively)(Fig. 6E).
Conclusions
Better characterization of placental vesicles is required to
understand their role in both physiological and pathological
pregnancies. The present study set out to address this issue. By
developing a multi colour flow cytometric methodology for use
with STBM preparations, we were able to investigate purity of
placental MV preparations and the presence of PE related
antigens on STBM from placentas of normal healthy pregnancies
and those affected by PE, prepared using two methods. Employing
NTA technology also allowed the investigation of the effects of
preparation method and PE on size distribution of ex vivo
prepared placental vesicles. The two techniques complement each
other with flow cytometry detecting and phenotyping the larger
MV (,300 nm21 mm) and the superior sensitivity of NTA
allowing analysis of exosomes and smaller MV (,50–400 nm).
Figure 3. Bar charts showing results of multi-colour flow cytometry analysis of (A) mechanically derived (mSTBM) and (B) perfusion
derived (pSTBM) placental vesicle preparations. (i) Percentage positive events and (ii) mean fluorescence intensity of placental alkaline
phosphatase (PLAP), Flt-1 (vascular endothelial cell growth factor receptor-1) and endoglin stained total microvesicle (MV) population (for PLAP) and
STB derived MV (for Flt-1 and endoglin). p values within a barchart are a comparison between PE and normal whereas * denotes a comparison
between mSTBM and pSTBM. *P,0.05 compared with normal mSTBM.
doi:10.1371/journal.pone.0056754.g003
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We have confirmed, in parallel, the presence of exosomes in the
different STBM preparations by western blotting for common
exosome markers (LAMP1, Alix, CD63 and CD9).
Multicolour flow cytometry has enabled us to accurately assess
the purity of the placental MV preparations. When analysing MV
by flow cytometry every precaution needs to be taken to reduce
the background event count, such as filtration of buffers and
regular cleaning of the machine. By initially using bio-maleimide
staining to identify the total MV population, we were able to
further minimize the contribution of non-cellular derived particles
to the overall analysis. By triple labeling samples with bio-
maleimide and NDOG2 and W6/32 antibodies the percentage of
the total MV population derived from STB produced by perfusion
was shown to be consistently high, in agreement with those
reported by Guller et al (2011) of 93–95%. No major effect of
preparation method or PE on the levels of PLAP positive MV was
seen, apart from a modest decrease in PLAP positive pSTBM
derived from PE placentas. Decreased PLAP expression, rather
than an increase in the proportion of contaminating vesicles was
confirmed by a significant decrease in PLAP MFI and by a
significant decrease in pSTBM PLAP expression using western
blotting. This suggests that a difference in STBM content does not
account for the previously reported variation in biological activity
of mSTBM and pSTBM [14].
During placental perfusion, STBM release occurs in conditions
mimicking the in vivo environment ie. the architecture of the
placental tissue is conserved and the integrity of the STB layer
maintained, unlike mechanical disruption where extensive damage
of the villous tissue occurs. Likewise, PE is associated with
placental disruption, shown by abnormal STB turnover, with
increased trophoblast apoptosis [36] and necrosis, resulting in
increased release of placental debris into the maternal circulation
[5,7], suggesting that PE placentas are compromised prior to the
ex vivo production of STBM, damage that could alter the
mechanism of release, size and phenotype of MV. Mechanical
disruption increased the proportion of vesicles .1 mm, measured
by flow cytometry, suggestive of an increase in apoptotic and
necrotic vesicles [21]. As polystyrene beads have a higher
refractive index then extracellular vesicles [37] the true size of
the vesicles detected by flow cytometry could be much larger, as
such, an effect of PE also on vesicles .1 mm cannot be ruled out.
PE and mechanical disruption both increased the mean and modal
size of vesicles detectable by NTA, suggesting that release of
vesicles in the smaller size range is also affected. NTA analysis of
pSTBM showing a shift in MV size profile with PE suggests an
imbalance between exosome and MV release and a shift towards
increased proinflammatory activity. This supports the results of
Holder et al 2012, with electron microscopic analysis suggesting
the release of larger and more disrupted MV with greater
inflammatory activity from cultured PE placental explants
compared to those from normal pregnancy. Increased STB
apoptosis may also decrease exosome production as reported for
tumour cells in culture [38]. This raises the question of whether
reduced exosome production and/or increased large MV release
ex vivo reflects the in vivo situation and whether this occurs during
the early stages of pregnancy when immune modulation is critical
to placental development [20,39].
Figure 4. Western blotting analysis of placental vesicle preparations. A) Representative immunoblot images and B) the corresponding
densitometric analysis of placental alkaline phosphatase (PLAP), VEGF receptor-1 (Flt-1) and endoglin in syncytiotrophoblast microvesicles (STBM)
prepared by i) mechanical disruption (mSTBM) and ii) placental perfusion (pSTBM) of normal and preeclampsia (PE) affected pregnancies. P values
show the comparison between normal and PE derived pSTBM.
doi:10.1371/journal.pone.0056754.g004
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By using multicolour flow cytometry we have conclusively
demonstrated that anti-angiogenic factors endoglin and Flt-1,
implicated in the pathogenesis of PE are associated with STBM,
extending the results of Guller et al 2011, showing perfused
placenta MV associated Flt-1 and endoglin by single colour flow
cytometry, and Rajakumar et al 2012, who demonstrated the
release of MV associated sFlt-1 from cultured placental explants
by ELISA. Decreased release of endoglin positive STBM from PE
placentas and reduced PLAP and endoglin expression on
mSTBM, suggests STB dysfunction affects surface antigen
Figure 5. Interaction of placental vesicle preparations with angiogenic factors. Binding of Ai) VEGF121, VEGF165 and PlGF and Aii) TGFb to
increasing amounts of pooled mSTBM from 13 normal placentas. B) Representative fluorescence micrographs and C) the corresponding percentage
coverage data for human umbilical vein endothelial cell monolayers treated with VEGF121, VEGF165, PlGF and TGFb (100 ng/mL) in the presence and
absence of normal mSTBM (75 mg/mL, pool of 13 preparations). Median values are indicated on the graphs. **P,0.001 compared with untreated
control wells.
doi:10.1371/journal.pone.0056754.g005
Figure 6. Analysis of vesicle size distribution and exosome marker expression of SH-SY5Y neuroblastoma cell line and placental
vesicle preparations. Nanosight Tracking Analysis size distribution profiles for (A) a representative SH-SY5Y neuroblastoma cell line exosome
preparation, (B) mechanically derived syncytiotrophoblast microvesicle preparations and (C) placental perfusion (pSTBM) from normal (norm) and
preeclampsia. (D) Representative immunoblot images and (E) the corresponding densitometric analysis of the exosome markers Lamp I, Alix, CD63
and CD9 in i) mSTBM and ii) pSTBM. Densitometric values were normalized using actin as a loading control.
doi:10.1371/journal.pone.0056754.g006
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expression. Tissue disruption and increased STB enzyme expres-
sion [40,41] associated with mSTBM production and PE placentas
could lead to increased release of enzymes, such as MMP-14 that
cleaves the extracellular domain of endoglin forming soluble
endoglin [41]. Therefore, as well as MV associated endoglin,
cleaved placental surface endoglin may also add to the increase in
circulating levels associated with PE [42]. The mechanism of
release of the GPI anchored PLAP is poorly understood and
reports of circulating PLAP levels in PE variable [43,44]. We
however have shown a consistent decrease in PLAP expression on
PE placenta derived STBM by flow cytometry and WB suggesting
that PLAP is not an appropriate marker for the detection of
circulating STBM in PE.
As well as surface Flt-1, perfusion and mSTBM contain several
isoforms of sFlt-1, the quantities of which are increased in PE
derived STBM. Soluble Flt-1 is therefore released from STB as
both intravesicular and membrane bound forms. The sFlt-1
isoforms found in the present study mirror those found by
Rajakumar et al 2012 in both normal pregnancy and PE plasma
and placental explant ultracentrifuged pellet. Endoglin expression
was also higher on PE placenta derived mSTBM. The extent to
which placenta derived MV associated proteins reflect protein
composition of the source STB was not investigated, but it has
been established that placental production and expression of
soluble Flt-1 and endoglin is increased by hypoxia and in PE
placentas [45]. This would suggest that the increased endoglin and
sFlt-1 associated with STBM measured by flow cytometry and WB
respectively, is reflective of the placenta from which the STBM
originated.
With the demonstration that STBM have the ability to bind the
proangiogenic factors VEGF, PlGF and TGFb and the observa-
tion of increased levels of STBM in the circulation of PE women
[5–7], this constitutes a significant capacity of STBM to bind
VEGF, PlGF and TGFb. Indeed, our observations that addition of
VEGF, PlGF and TGF reversed the disruptive effects of mSTBM
on cultured HUVEC monolayers demonstrates further the
potential sequestering and inhibition of growth factors vital for
the maintenance of the vascular endothelium by STBM and also
extends previously published results showing that inhibition of
endothelial tube formation by MV released from PE placental
explant can be reversed by VEGF supplementation [15].
Furthermore, sFlt-1 targeted treatments as a therapy for PE, such
as VEGF supplementation or reduction of circulating sFlt-1 levels
have shown alleviation of symptoms in animal models of PE [46–
48]. The question remains as to the biological significance of MV
associated and soluble endoglin and Flt-1. The potential for
STBM to accumulate in filtering organs such as the liver and
spleen [49,50], implicates MV delivery of antiangiogenic factors in
the organ endothelial dysfunction intrinsic to the maternal
syndrome of PE.
The growing number of factors associated with STBM suggests
that they are complex entities with the potential to affect multiple
biological systems. The balance between the immunosuppressive
exosomes and proinflammatory MV gives an additional dimension
to the role of syncytiotrophoblast derived vesicles during normal
pregnancy and PE. As circulating biopsies of the placenta, the
characterisation of STBM is essential to better understand, not
only the biological effects but also their potential as prognostic and
diagnostic biomarkers for early detection of PE. Also, the release of
significant quantities of placental MV carrying biologically active
moieties broadens the maternal-fetal interface beyond the uterus
and into the maternal circulation.
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